Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of the Oxadiazine FRM-024: A Potent CNS-Penetrant Gamma Secretase Modulator.
Bursavich MG, Harrison BA, Acharya R, Costa DE, Freeman EA, Hrdlicka LA, Jin H, Kapadnis S, Moffit JS, Murphy D, Nolan SJ, Patzke H, Tang C, Van Voorhies HE, Wen M, Koenig G, Blain JF, Burnett DA. Bursavich MG, et al. Among authors: kapadnis s. J Med Chem. 2021 Oct 14;64(19):14426-14447. doi: 10.1021/acs.jmedchem.1c00904. Epub 2021 Sep 22. J Med Chem. 2021. PMID: 34550687
Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
Blain JF, Bursavich MG, Freeman EA, Hrdlicka LA, Hodgdon HE, Chen T, Costa DE, Harrison BA, Kapadnis S, Murphy DA, Nolan S, Tu Z, Tang C, Burnett DA, Patzke H, Koenig G. Blain JF, et al. Among authors: kapadnis s. Alzheimers Res Ther. 2016 Aug 30;8(1):34. doi: 10.1186/s13195-016-0199-5. Alzheimers Res Ther. 2016. PMID: 27572246 Free PMC article.
Design, Synthesis, and Evaluation of a Novel Series of Oxadiazine Gamma Secretase Modulators for Familial Alzheimer's Disease.
Bursavich MG, Harrison BA, Acharya R, Costa DE, Freeman EA, Hodgdon HE, Hrdlicka LA, Jin H, Kapadnis S, Moffit JS, Murphy DA, Nolan S, Patzke H, Tang C, Wen M, Koenig G, Blain JF, Burnett DA. Bursavich MG, et al. Among authors: kapadnis s. J Med Chem. 2017 Mar 23;60(6):2383-2400. doi: 10.1021/acs.jmedchem.6b01620. Epub 2017 Mar 10. J Med Chem. 2017. PMID: 28230986
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.
Hopkins BT, Bame E, Bajrami B, Black C, Bohnert T, Boiselle C, Burdette D, Burns JC, Delva L, Donaldson D, Grater R, Gu C, Hoemberger M, Johnson J, Kapadnis S, King K, Lulla M, Ma B, Marx I, Magee T, Meissner R, Metrick CM, Mingueneau M, Murugan P, Otipoby KL, Polack E, Poreci U, Prince R, Roach AM, Rowbottom C, Santoro JC, Schroeder P, Tang H, Tien E, Zhang F, Lyssikatos J. Hopkins BT, et al. Among authors: kapadnis s. J Med Chem. 2022 Jan 27;65(2):1206-1224. doi: 10.1021/acs.jmedchem.1c00926. Epub 2021 Nov 4. J Med Chem. 2022. PMID: 34734694
Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
Rowbottom C, Pietrasiewicz A, Tuczewycz T, Grater R, Qiu D, Kapadnis S, Trapa P. Rowbottom C, et al. Among authors: kapadnis s. Pharmacol Res Perspect. 2021 Apr;9(2):e00740. doi: 10.1002/prp2.740. Pharmacol Res Perspect. 2021. PMID: 33660938 Free PMC article.
Pyloric atresia--three cases and review of literature.
Parelkar SV, Kapadnis SP, Sanghvi BV, Joshi PB, Mundada D, Shetty S, Oak SN. Parelkar SV, et al. Among authors: kapadnis sp. Afr J Paediatr Surg. 2014 Oct-Dec;11(4):362-5. doi: 10.4103/0189-6725.143178. Afr J Paediatr Surg. 2014. PMID: 25323191 Review.
20 results